Elise J Smolders1, Colette Smit, Clara T M M de Kanter, Anton S M Dofferiiof, Joop E Arends, Kees Brinkman, Bart Rijnders, Marc van der Valk, Peter Reiss, David M Burger. 1. *Department of Pharmacy, Radboud Institute of Health Sciences (RIHS) and Radboud university medical center, Nijmegen, the Netherlands; †HIV Monitoring Foundation, Amsterdam, the Netherlands; ‡Department of Pharmacy, University Medical Center Utrecht, Utrecht, the Netherlands; §Department of Internal Disease and Infectious Diseases, Radboud university medical center, Nijmegen, the Netherlands; ‖Department of Internal Medicine and Infectious Diseases, University Medical Center, Utrecht, the Netherlands; ¶Department of Internal Medicine and Infectious Diseases, OLVG, Amsterdam, the Netherlands; #Department of Internal Medicine and Infectious Diseases, Erasmus MC University Medical Center, Rotterdam, the Netherlands; **Academic Medical Center, Division of Infectious Diseases, and Center for Infection and Immunity Amsterdam (CINIMA), Amsterdam, the Netherlands; and ††Department of Global Health and Amsterdam Institute for Global Health and Development, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands.
Abstract
BACKGROUND: To describe the use of nonantiretroviral comedication and combination antiretroviral therapy (cART) in patients coinfected with HIV/hepatitis C virus (HCV) and to predict the potential for drug-drug interactions (DDIs) with direct-acting antivirals (DAAs) against HCV. METHODS: This is a retrospective, cross-sectional study, using the Dutch, nationwide ATHENA observational HIV cohort database. All patients with a known HIV/HCV coinfection on January 1, 2015, were included. Comedication and cART registered in the database were listed. The potential for DDIs between DAAs and comedication/cART were predicted using http://hep-druginteractions.org. DDIs were categorized as: (1) no clinically relevant DDI; (2) possible DDI; (3) contraindication; or (4) no information available. RESULTS: We included 777 patients of whom 488 (63%) used nonantiretroviral comedication. At risk for a category 2/3 DDI with nonantiretroviral comedications were 299 patients (38%). Most DDIs were predicted with paritaprevir/ritonavir, ombitasvir ± dasabuvir (47% of the drugs) and least with grazoprevir/elbasvir (11% of the drugs). Concerning cART, daclatasvir/sofosbuvir is the most favorable combination as no cART is contraindicated with this combination. In genotype 1/4 patients, grazoprevir/elbasvir is least favorable as 75% of the patients must alter their cART. CONCLUSIONS: This study showed that comedication use in the aging HIV/HCV population is frequent and diverse. There is a high potential for DDIs between DAAs and comedication/cART.
BACKGROUND: To describe the use of nonantiretroviral comedication and combination antiretroviral therapy (cART) in patients coinfected with HIV/hepatitis C virus (HCV) and to predict the potential for drug-drug interactions (DDIs) with direct-acting antivirals (DAAs) against HCV. METHODS: This is a retrospective, cross-sectional study, using the Dutch, nationwide ATHENA observational HIV cohort database. All patients with a known HIV/HCV coinfection on January 1, 2015, were included. Comedication and cART registered in the database were listed. The potential for DDIs between DAAs and comedication/cART were predicted using http://hep-druginteractions.org. DDIs were categorized as: (1) no clinically relevant DDI; (2) possible DDI; (3) contraindication; or (4) no information available. RESULTS: We included 777 patients of whom 488 (63%) used nonantiretroviral comedication. At risk for a category 2/3 DDI with nonantiretroviral comedications were 299 patients (38%). Most DDIs were predicted with paritaprevir/ritonavir, ombitasvir ± dasabuvir (47% of the drugs) and least with grazoprevir/elbasvir (11% of the drugs). Concerning cART, daclatasvir/sofosbuvir is the most favorable combination as no cART is contraindicated with this combination. In genotype 1/4 patients, grazoprevir/elbasvir is least favorable as 75% of the patients must alter their cART. CONCLUSIONS: This study showed that comedication use in the aging HIV/HCV population is frequent and diverse. There is a high potential for DDIs between DAAs and comedication/cART.
Authors: Georg Dultz; Tobias Müller; Jörg Petersen; Stefan Mauss; Tim Zimmermann; Marion Muche; Karl-Georg Simon; Thomas Berg; Stefan Zeuzem; Dietrich Hüppe; Klaus Böker; Heiner Wedemeyer; Tania M Welzel Journal: Drugs Aging Date: 2018-09 Impact factor: 4.271